Status:
UNKNOWN
Efficacy and Safety of Covid-19 Vaccine in Cardiac Patients
Lead Sponsor:
Mina sobhi said fam
Collaborating Sponsors:
Assiut University
Conditions:
COVID-19 Vaccine
Eligibility:
All Genders
18-80 years
Brief Summary
Efficacy and safety of covid-19 vaccine in Cardiac patients
Detailed Description
investigate the efficacy and safety of covid-19 vaccine in cardiac patients and its possible assocciated morbidity
Eligibility Criteria
Inclusion
- Subjects diagnosed as STEMI undergo PPCI as (Fourth universal definition of myocardial infarction (2018) Kristian Thygesen) 10
- with age range from 18 to 80 years after 1 month of STEMI .
Exclusion
- Patients with previous covid infection confirmed by swap or CT chest or ICU addmision.
- Patients with previous covid infection confirmed by qualitative antibdy test .
- Patients with history of anaphylaxis to any component of the vaccine should not take it .
- patients with febrile illness or acute , ongoing infection .
- immunosuppressive diseases .
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05348629
Start Date
June 1 2022
End Date
September 1 2023
Last Update
April 27 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University
Asyut, Egypt, 71515
2
Assiut university
Asyut, Egypt, 71515